Orla Hardiman
Orla Hardiman
Trinity College Dublin
Bestätigte E-Mail-Adresse bei - Startseite
Zitiert von
Zitiert von
Amyotrophic lateral sclerosis
MC Kiernan, S Vucic, BC Cheah, MR Turner, A Eisen, O Hardiman, ...
The lancet 377 (9769), 942-955, 2011
Amyotrophic lateral sclerosis
O Hardiman, A Al-Chalabi, A Chio, EM Corr, G Logroscino, W Robberecht, ...
Nature reviews Disease primers 3 (1), 1-19, 2017
Amyotrophic lateral sclerosis
MA Van Es, O Hardiman, A Chio, A Al-Chalabi, RJ Pasterkamp, ...
The Lancet 390 (10107), 2084-2098, 2017
Prognostic factors in ALS: a critical review
A Chio, G Logroscino, O Hardiman, R Swingler, D Mitchell, E Beghi, ...
Amyotrophic lateral sclerosis 10 (5-6), 310-323, 2009
EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force
EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:
European journal of neurology 19 (3), 360-375, 2012
Incidence of amyotrophic lateral sclerosis in Europe
G Logroscino, BJ Traynor, O Hardiman, A Chiò, D Mitchell, RJ Swingler, ...
Journal of Neurology, Neurosurgery & Psychiatry 81 (4), 385-390, 2010
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
The epidemiology of ALS: a conspiracy of genes, environment and time
A Al-Chalabi, O Hardiman
Nature Reviews Neurology 9 (11), 617-628, 2013
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis
MJ Greenway, PM Andersen, C Russ, S Ennis, S Cashman, C Donaghy, ...
Nature genetics 38 (4), 411-413, 2006
The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study
J Phukan, M Elamin, P Bede, N Jordan, L Gallagher, S Byrne, C Lynch, ...
Journal of Neurology, Neurosurgery & Psychiatry 83 (1), 102-108, 2012
Clinical diagnosis and management of amyotrophic lateral sclerosis
O Hardiman, LH Van Den Berg, MC Kiernan
Nature reviews neurology 7 (11), 639-649, 2011
Cognitive impairment in amyotrophic lateral sclerosis
J Phukan, NP Pender, O Hardiman
The Lancet Neurology 6 (11), 994-1003, 2007
Controversies and priorities in amyotrophic lateral sclerosis
MR Turner, O Hardiman, M Benatar, BR Brooks, A Chio, M De Carvalho, ...
The Lancet Neurology 12 (3), 310-322, 2013
Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis
W Van Rheenen, A Shatunov, AM Dekker, RL McLaughlin, FP Diekstra, ...
Nature genetics 48 (9), 1043-1048, 2016
Genome-wide analyses identify KIF5A as a novel ALS gene
A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ...
Neuron 97 (6), 1267-1288, 2018
Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
G Logroscino, BJ Traynor, O Hardiman, P Couratier, JD Mitchell, ...
Journal of Neurology, Neurosurgery & Psychiatry 79 (1), 6-11, 2008
Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000
BJ Traynor, M Alexander, B Corr, E Frost, O Hardiman
Journal of Neurology, Neurosurgery & Psychiatry 74 (9), 1258-1261, 2003
Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study
S Byrne, M Elamin, P Bede, A Shatunov, C Walsh, B Corr, M Heverin, ...
The Lancet Neurology 11 (3), 232-240, 2012
Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study
BJ Traynor, MB Codd, B Corr, C Forde, E Frost, OM Hardiman
Archives of neurology 57 (8), 1171-1176, 2000
ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)
N Parkinson, PG Ince, MO Smith, R Highley, G Skibinski, PM Andersen, ...
Neurology 67 (6), 1074-1077, 2006
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20